Belumosudil pill vs crushed pill study for chronic GVHD

This trial tests a pill called belumosudil to see if it can help people with chronic graft-versus-host disease (a common complication after a stem cell transplant where donor cells attack your body). It is for patients who have symptoms but are not yet on strong immune-suppressing drugs.

This study tests a new medicine called belumosudil for children with chronic graft-versus-host disease (GVHD) that hasn't improved with at least 2 other treatments. The goal is to see if it can help control the disease and improve symptoms.

This study tests a new medication called belumosudil to see how safe it is for people with chronic graft-versus-host disease (cGVHD). If you have had a stem cell transplant and still need treatment for cGVHD after trying other therapies, this trial may be an option.

This study tests two forms of the drug belumosudil (a liquid and a tablet) to see if they work the same in the body. It's for healthy men and will help decide which version may be easier for patients to take.

This study tests a new medicine called belumosudil for chronic graft-versus-host disease (cGVHD), a condition where donor cells attack the body after a stem cell transplant. The trial compares belumosudil to the best available standard treatments to see if it works better at controlling the condition.

This trial tests a combination of two drugs, belumosudil and rituximab, as the first treatment for chronic graft-versus-host disease (cGVHD), a complication that can occur after a stem cell transplant. The goal is to see if this combination can control symptoms and reduce the need for steroids.